Managing residual inflammatory risk in atherosclerotic cardiovascular disease: another piece of the puzzle?

Yu-Xiang Dai,Jun-Bo Ge

DOI: https://doi.org/10.1097/CP9.0000000000000005

2022-01-01

Cardiology Plus

Abstract:Hypercholesterolemia is recognized as the basis of atherosclerotic cardiovascular diseases (ASCVD)[1,2]. Accordingly, lowering blood lipids, and particularly low-density lipoprotein cholesterol (LDL-C), is the cornerstone of secondary prevention of ASCVD. Agents with proven efficacy included a variety of statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors[3,4], and ezetimibe[5]. Elevated cholesterol, however, is not the sole modifiable risk. This review summarizes the recent evidence for residual inflammatory risk for ASCVD. Epidemiological and biological studies have demonstrated that inflammation participate in the initiation and progression of coronary atherosclerosis[6,7]. Circulating inflammatory biomarkers, including hsCRP and interleukin-6 (IL-6), are associated with cardiovascular events independent of cholesterol and other traditional risk factors. Uncontrolled inflammation renders coronary plaques vulnerable to rupture or erosion, and ultimately acute coronary events[8,9]. Several recent trials have established the benefit of anti-inflammatory therapy in high-risk patients. In the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS)[10], a total of 10,061 patients with residual inflammatory risk (on-treatment circulating high-sensitivity C-reactive protein ≥2 mg/L) after myocardial infarction (MI) were randomized to receive canakinumab, a monoclonal neutralizing interleukin-1β (IL-1β) antibody versus the placebo. The trial demonstrated 15% reduction in major adverse cardiovascular events (MACEs) and 17% reduction in MACEs plus urgent revascularization, independent of lipid lowering[11]. The results of the CANTOS re-ignited the interest in anti-inflammatory therapy for CAD. However, canakinumab is expensive and associated with a small but clinically significant increase in fatal infection or sepsis. Subsequent attempts have been made to re-purpose anti-inflammatory agents already on-market as alternatives. Notably, fewer cardiovascular events have been noticed in patients receiving low-dose methotrexate for rheumatoid arthritis or psoriatic arthritis in observational studies[12,13]. The Cardiovascular Inflammation Reduction Trial (CIRT)[14] enrolled 4,786 patients with previous MI or multivessel coronary disease with either type 2 diabetes or metabolic syndrome, but failed to show similar cardiovascular benefit as canakinumab with low-dose methotrexate (target dose: 15–20 mg weekly). Specifically, methotrexate did not reduce either MACEs or plasma markers of inflammation[15]. Failure of the CIRT has been putatively attributed to several factors. First, patients in the CIRT had lower hsCRP at the baseline compared with CANTOS (median of 1.5 mg/L in CIRT vs. 4.2 mg/L in CANTOS). Second, methotrexate does not target the IL-1β-IL-6 signaling pathway. The discrepancy between the CANTOS and CIRT suggested that targeting specific anti-inflammatory pathway is crucial. The Low-Dose Colchicine (LoDoCo) study[16] is an earlier open-label trial in 532 patients with stable coronary disease (clinically stable for at least 6 months), and showed fewer cardiovascular events in patients receiving colchicine (0.5 mg/day) in addition to versus statins and other standard secondary prevention therapies alone. The efficacy of colchicine was later verified in patients with a recent myocardial infarction by a much larger (n = 4,745) placebo-controlled, double-blinded Colchicine Cardiovascular Outcomes Trial (COLCOT)[17]. In comparison to antiplatelet and statins therapy alone, adding colchicine (0.5 mg/day) resulted in 23% relative reduction in the primary composite efficacy end point over a 2-year period, including death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization. The reduction was predominantly due to lower incidence of stroke and urgent hospitalization for angina leading to coronary revascularization. Magnitude of the benefit with colchicine in the COLCOT seems to be larger than with canakinumab in the CANTOS, suggesting patients with acute ASCVD are particularly suitable candidates for anti-inflammatory treatment. The subsequent LoDoCo2[18] verified cardiovascular protective effect of colchicine (0.5 mg/day) in 5,522 patients with chronic coronary disease. Specifically, the relative risk of the composite primary endpoint that included cardiovascular death, spontaneous myocardial infarction, ischemic stroke, and ischemia-driven coronary revascularization was reduced by 31%. Evidence from the clinical trials described above confirmed that reducing residual inflammatory risk is important in managing CVD. Anti-inflammatory treatment should be included as an important part of the secondary prevention of ASCVD in high-risk patients. However, it should be noticed that anti-inflammatory drugs that target different molecular pathways may have differential effects. Agents targeting the NLRP3 inflammasome-IL-1β-IL-6 signaling pathway, including canakinumab and colchicine, have been shown to reduce cardiovascular events. Considering the well-established safety profile and cost-effectiveness, colchicine represents a viable option. Conflict of interest statement Jun-Bo Ge is an Editorial Board member of Cardiology Plus. The article was subject to the journal's standard procedures, with peer review handled independently of this Editorial Board member and their research groups.